Search

EHA-BSH joint membership

Save money and time by becoming a joint member of EHA and the British Society of Haematology. We've joined forces with the British Society of Haematology (BSH) to offer a special joint membership deal.

Read more

EHA-SEHH joint membership

Save money and time by becoming a joint member of EHA and the Sociedad Española de Hematología y Hemotherapia. We've joined forces with the Sociedad Española de Hematología y Hemotherapia (SEHH) to offer a special joint membership deal.

Read more

EHA-SIE joint membership

Save money and time money by becoming a joint member of EHA and the Società Italiana di Ematologia. We've joined forces with the Società Italiana di Ematologia (SIE) to offer a special joint membership deal.

Read more

EHA-SSH joint membership

Save money and time by becoming a joint member of EHA and the Swiss Society of Hematology. We've joined forces with the Swiss Society of Hematology (SSH) to offer a special joint membership deal.

Read more

Special airfare discount

A 10% discount on Air France or KLM airfares for EHA2025 attendees. If you'll be flying to EHA2025, you can benefit from a special discount courtesy of Air France-KLM Global Meetings & Events.

Read more

Turning thoughts into reality

Turning thoughts into reality
By Dr Adi Zoref (@ZorefAdi)

I am an Israeli physician, trained in internal medicine. During my residency rotation in hematology at Meir Medical Center, I met a patient who changed my life.

Read more

EHA remembers Tessa Holyoake

The Hague, September 2017

We received the sad news of Professor Tessa Holyoake’s passing. Tessa Holyoake was a Professor of Experimental Hematology and the Head of the Paul O'Gorman Leukemia Research Centre.

Read more

‘Rare Cancers in all EU policies’: Prof Elizabeth Macintyre expresses strong EHA support for the Rare Cancers Europe agenda

On September 28, EHA President Elizabeth Macintyre addressed an audience that included Members of the European Parliament, and officials of the European Commission and the European Medicines Agency, as well as members of the Rare Cancers Europe (RCE) partnership.

Read more

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more